EVLO | Evelo Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0001 - 0.0001
52 Week Range	0.0001 - 5.27
Beta	1.84
Implied Volatility	547.28%
IV Rank	61.50%
Day's Volume	100
Average Volume	3,964
Shares Outstanding	18,982,800
Market Cap	1,898
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-05-08

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-15.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	66
Country	USA
Website	EVLO

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

EVLO's peers: ALRN, ABVC, HROW, SRZN

*Chart delayed

Analyzing fundamentals for EVLO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see EVLO Fundamentals page.

Watching at EVLO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EVLO Technicals page.